

4 December 2024

IXICO PLC

("IXICO" or the "Company")

Share Option Award & Director Bid & ISA Dealings

PDMR Dealing

Share Option Award:

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering insights in neurosciences, today announces that it has issued a total of 500,000 options to subscribe for ordinary shares of 1 pence each in the Company (the "**Share Options**") to Robin Wolz, CSO and a PDMR of the Company.

In recognition of his increasing contribution to the continued success of the Group, the Board has decided to provide Mr Wolz with share option performance criteria that is aligned with the Group's Executive Directors.

The Share Options have vesting criteria aligned with retention and annual share price growth over 3 years. These options have an exercise price of £0.01 and will be subject to a hold period to the third anniversary of their award.

The achievement of share price growth each year shall be measured by calculating the 3-month average share price immediately prior to each anniversary of the option award. The growth performance can be met in full by an absolute compound share price growth of 40% over the three-year period or in part by a 40% share price growth as compared to the prior year. In the first year this shall be compared to a baseline price equivalent to the three-month average share price immediately prior to the CEO joining the Company on 19 August 2024.

It is further announced that 200,000 options awarded to Mr Wolz on 30 October 2024 lapsed in full with effect from 28 November 2024.

Director Bid & ISA Dealings:

In addition, the Company announces that it received notification on 4 December 2024, that Grant Nash, CFO and PDMR, sold 260,000 ordinary shares of 1p each in the Company and repurchased 260,000 ordinary shares into Mr Nash's ISA account. Following this transaction Mr Nash's beneficial interest in the Company's shares has not changed.

The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further detail.

For further information please contact:

IXICO plc

Bram Goorden, Chief Executive Officer
Grant Nash, Chief Financial Officer

+44 (0) 20 3763 7499

**Cavendish Capital Markets Limited
(Nominated adviser and sole broker)**

Giles Balleny / Dan Hodgkinson (Corporate Finance)
Nigel Birks (Life Sciences Specialist Sales)
Harriet Ward (Corporate Broking)
Michael F Johnson / Tamar Cranford Smith (Sales)

+44 (0) 20 7220 0500

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on X (formerly Twitter) @IXICOnews

1	Details of the person discharging managerial responsibilities / person closely associated					
a)	Name	Robin Wolz				
2	Reason for the notification					
a)	Position/status	Chief Scientific Officer and PDMR				
b)	Initial notification /Amendment	Initial				
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
a)	Name	IXCO plc				
b)	LEI	2138005M1F59O6HWSA97				
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument, type of instrument Identification code	Options over ordinary shares in IXCO plc ISIN: GB00BFXR4C20				
b)	Nature of the transaction	Grant of Share Options				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>1 pence</td> <td>500,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	1 pence	500,000
Price(s)	Volume(s)					
1 pence	500,000					
d)	Aggregated information - Aggregated volume - Price	N/A - single transaction				
e)	Date of the transaction	4 December 2024				
f)	Place of the transaction	Off Market Transaction				

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Grant Nash
2	Reason for the notification	
a)	Position/status	Chief Financial Officer and PDMR
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	IXCO plc

a)	Name	IXCO plc							
b)	LEI	2138005M1F59O6HWSA97							
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted								
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares in IXCO plc ISIN: GB00BFXR4C20							
b)	Nature of the transaction	Sale and purchase of ordinary shares							
c)	Price(s) and volume(s)	<table><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>Sale at 12.000p</td><td>260,000</td></tr><tr><td>Purchase at 12.015p</td><td>260,000</td></tr></table>		Price(s)	Volume(s)	Sale at 12.000p	260,000	Purchase at 12.015p	260,000
Price(s)	Volume(s)								
Sale at 12.000p	260,000								
Purchase at 12.015p	260,000								
d)	Aggregated information - Aggregated volume - Price	N/A							
e)	Date of the transaction	4 December 2024							
f)	Place of the transaction	Off Market Transaction							

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHFSDFFLELSEDE